LabCorp

Q4 Results Q/Q Comparison:

  • Revenue increased 48% to $2.24B
    • LabCorp Diagnostics increased 4.3% to $1.55B
    • Covance Drug Development increased 4.7% to $691.4M
  • GAAP Diluted EPS decreased 20% to $1.11
    • Adjusted EPS increased 20% to $1.98
  • Adjusted Operating Income increased 12% to $368M
    • LabCorp Diagnostics increased 7% to $293M
    • Covance Drug Development increased 23% to $110M
  • Adjusted Operating margin of 16.4%, up from 15.3%
    • LabCorp Diagnostics: 18.9%, up from 18.4%
    • Covance Drug Development: 16.0%, up from 13.6%

Full-year 2015 Results Q/Q Comparison:

  • Revenue increased 42% to $8.84B
    • LabCorp Diagnostics increased 5% to $6.21B
    • Covance Drug Development increased 1% to $2.63B
  • GAAP Diluted EPS decreased 27% to $4.34
    • Adjusted EPS increased 16% to $7.91
  • Adjusted Operating Income increased 11% to $1.48B
    • LabCorp Diagnostics increased 10% to $1.24B
    • Covance Drug Development increased 9% to $372M
  • Adjusted Operating margin of 16.7%, up from 15.6%
    • LabCorp Diagnostics: 20.0%, up from 19.1%
    • Covance Drug Development: 14.1%, up from 13.0%
  • Free cashflow increased 36% to $727M
  • Year-end cash of $716M and debt of $6.42B

2016 Guidance:

  • Revenue growth of 7.5% to 9.5%
  • Adjusted EPS of $8.45 to $8.85 (an increase of 7% to 12%)
  • Free cash flow of $900M to $950M (an increase of 24% to 31%)

Stock Price: $109
Market Capitalization: $11.1 billion

February 18, 2016

 

 

 


 


 

Menu byMilonic